×

Bioverativ's hemophilia hopes

7:18 AM ET Wed, 15 Feb 2017

CNBC's Meg Tirrell speaks with John Cox, Bioverativ CEO, about the company's spinoff from Biogen, its new innovations in treating hemophilia.